Taken together, our data demonstrate an enrichment of conventional Tc17 cells with a proinflammatory cytokine profile in active CD, identify phenotypic markers for this Tc17 subset and highlight components of the Tc17 signature, such as CD6, as potential therapeutic targets in IBD. This evidence concerns the gene CD6 and Cowden disease.